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methylcelluloseAbstract A single unit sustainable drug release system was developed using hydroxypropyl
methylcellulose (HPMC)-based matrices ﬁlled in capsule as the drug delivery device. Release behav-
ior of propranolol HCl from these capsules was investigated and least square ﬁtting was performed
for the dissolution data with the different mathematical expressions. Effect of diluent, polymer, pH
and hydrodynamic force on the drug release from the developed systems was investigated. The uti-
lization of HPMC as a matrix former extended the drug release longer than 8 h. HPMC viscosity
grades affected the drug release, that is, increasing the amount of ﬁllers such as lactose and dibasic
calcium phosphate enhanced the drug release rate of HPMC matrices. The hydrodynamic force,
type and amount of incorporated polymer apparently inﬂuenced the drug release. The physiochem-
ical properties of polymers and interaction between HPMC and other polymers were important fac-
tors for prolongation of the drug release. The release mechanism from HPMC-based matrices in
capsules was the non-Fickian transport in which the sustainable drug release of HPMC capsules
could be achieved by the addition of polymeric matrix.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Typically, hard gelatin capsule is commonly used for ﬁlling
large number of drugs including antibiotics. The production
of pharmaceutical products in the form of capsules is both
cost- and process-effective. The utilization of capsules as acontrolled drug delivery device is also interesting. The lipid
system in a molten state can be directly ﬁlled into hard gelatin
capsules to control the drug release. A diffusion-controlled sys-
tem was obtained with Gelucire containing lithium sulfate,
which remained inert in the aqueous environment at 37 C.
On the contrary, the erosion was proved to control the release
of indomethacin when the dispersible Gelucire was added to
the non-dispersible Gelucire (Vial-Bernasconi et al., 1995).
Some retardation in urinary excretion was obtained for total
salicylate when administering capsules of aspirin mixed with
Gelucire 50/13 (Djimbo et al., 1984). For colon drug delivery
with a chitosan capsule, an additional outer enteric coating
prevented the drug release in the stomach owing to the solubil-
ity of chitosan under acidic conditions. Resultant enteric-
coated chitosan dispersed system capsules reached the large
Table 1 Tapped density of drug and materials (mean ± SD,
n= 3).
Materials Tapped density (g/mL)
PPH 0.42 ± 0.00
Chitosan (180 mesh passed) 0.32 ± 0.01
Dibasic calcium phosphate 0.86 ± 0.01
Ethyl cellulose 0.32 ± 0.00
HPMC K15M 0.46 ± 0.01
HPMC K4M 0.49 ± 0.00
HPMC K100M 0.48 ± 0.01
HPMC E15LV 0.51 ± 0.01
Lactose 0.67 ± 0.00
Sodium bicarbonate 0.67 ± 0.00
Xanthan gum 0.69 ± 0.02
628 T. Phaechamud, W. Darunkaisornintestine within 1–3 h after oral administration and they grad-
ually degraded in the colon (Shimono et al., 2002). Pulsatile
drug delivery system has been developed using a water insol-
uble capsule body and a hydrophilic plug (HPMC or guar
gum). The body portion was cross-linked by formaldehyde
and heat treatment which the drug was liberated from a limited
surface area of the open end of this hard gelatin capsule. This
design was similar to the Pulsincap system which had an
insoluble capsule body (Gothoskar et al., 2004). In addition,
the type of hydrophilic agent (HPMC or guar gum) and the
molecular weight of HPMC affected the drug release
(Mukesh and Sumitra, 2002).
Propranolol HCl (PPH) is widely used in therapeutics for its
antihypertensive and antiarrhythmic actions. It has a short
plasma half-life of about 2–6 h. Consequently, it has to be fre-
quently taken in order to maintain the plasma concentration in
the therapeutic range. The main purpose of the extended release
product is to reduce side effects and prolong the drug intake
interval and, thus, it is also convenient for drug administration.
Furthermore, being highly water soluble drug (Lund, 1994) it is
suitable to be used as model drug for this study to assess the
efﬁcacy of the developed system for prolongation of its release.
HPMC capsules do not become brittle when exposed to low
humidity and they are chemically stable. In addition, the
slower drug release from HPMC capsule than that from gela-
tin capsules has been reported (Cole et al., 2004). HPMC cap-
sules were used in this study to minimize the effect of charge
interaction, especially the positive charge of propranolol and
the negative charge of gelatin. HPMC has been employed
extensively as a hydrophilic matrix former in oral controlled-
release dosage forms for various drugs. This popularity can
be attributed to its non-toxic nature, its capability to accom-
modate high levels of drug loading in matrix and a small inﬂu-
ence of processing variables on drug release (Ganga et al.,
1992; Taylan et al., 1996; Chattaraj and Das, 1996). There
are many disadvantages for manufacturing matrix tablet
including the longer period and higher energy-consuming pro-
cess. In addition, some polymer using as matrix former renders
the granules elastic and the elastic deformation during the
compression leads to soft tablets with not adequate hardness.
For matrix ﬁlled in capsule, the cost of production will be min-
imized because of the lesser production steps and excipients in
formula. Although the single-unit matrices of PPH sustained
release tablets have been widely developed, in order to reduce
the frequency of dosing and to produce steady pharmacologi-
cal effects, the development of this drug into single HPMC
matrix ﬁlling into capsules has not been reported. The purpose
of this study was to develop PPH sustained release capsules
using different polymers as a matrix former and to investigate
the factors affecting the drug release from the prepared cap-
sules , which is the simplest way to make prolonged release for-
mulations. Authors need to highlight draw backs of matrix
tablets such as.
2. Materials and methods
2.1. Materials
PPH was purchased from China National Chemical Imp. &
Exp., Shanghai, China. HPMCs (Methocel K 4M,
Methocel K 15M, Methocel K 100M and Methocel E15LV were purchased from Colorcon Asia Paciﬁc Pvt., Ltd.,
Bangkok, Thailand. Chitosan (Aqua premier, Chonburi,
Thailand) with a degree of deacetylation of 99.3% and a
molecular weight of 70 kDa was passed through sieve No. 80
mesh before being used. Dibasic calcium phosphate (DPC)
(Sudeep Pharma Ltd., India), HCl (Baker Analyzed, A.C.S.
Reagent, USA), and xanthan gum (Xantural 75, CP Kelco
U.S., Inc. USA.) were used as received. Monobasic potassium
phosphate, sodium hydroxide pellets, sodium bicarbonate and
sodium chloride were purchased from P.C. Drug Center Co.,
Ltd., Thailand. HPMC capsules size No.1 were kindly sup-
plied by Capsugel, Pranakorn Sriauthuthaya, Thailand and
used as received.
2.2. Formulation and preparation of single-unit controlled
release capsules
Hard HPMC capsules (size No. 1 with a volume of
0.49 ± 0.01 mL) were ﬁlled with the drug and matrix compo-
nent. The amount of PPH per capsule was 40 mg. Different
viscosity grades of HPMC, i.e. Methocel type K4M,
K15M, K100M and E15LV, were utilized as a matrix former
to investigate the effect of viscosity grade of HPMC on the
drug release. A study was also performed for the effect of types
and amounts of diluents (lactose, dibasic calcium phosphate
(DPC) and sodium bicarbonate (NaHCO3)) and polymers
(chitosan and xanthan gum) on the drug release from
HPMC matrices. The tapped density of the excipients
(Table 1) was used to determine the amount to ﬁll into cap-
sules. The capsule formula presenting the excipient composi-
tion is shown in Table 2. The powders were mixed manually
with a mortar and pestle for 5 min to obtain the homogeneous
powder mix and ﬁlled in capsules using a capsule ﬁlling
machine No. 1 (S.T.P No.1 B.M., Bangkok, Thailand).
2.3. Evaluation of physical properties of capsule
Weight variation of capsules was determined by using an ana-
lytical balance. Twenty capsules were individually weighed.
The contents of each capsule were removed by using a suitable
means. The empty shells were individually accurately weighed
and calculated for the net weight of its contents by subtracting
the weight of the shell from the respective gross weight.
Table 2 Composition formula of PPH matrix capsules containing different diluents.
Formula Excipients (%w/v)
HPMC K4M HPMC K15M HPMC K100M HPMC E15LV Lactose DCP Xanthan gum Chitosan NaHCO3
F1 100 – – –
F2 – 100 – –
F3 – – 100 –
F4 – – – 100
F5 – 100 – – – –
F6 25 75 – – – –
F7 50 50 – – – –
F8 75 25 – – – –
F9 – – 100 – – –
F10 25 – 75 – – –
F11 50 – 50 – – –
F12 75 – 25 – – –
F13 – – – 100 – –
F14 25 – – 75 – –
F15 50 – – 50 – –
F16 75 – – 25 – –
F17 – – – – 100 –
F18 25 – – – 75 –
F19 50 – – – 50 –
F20 75 – – – 25 –
F21 40 – – – – 60
F22 60 – – – – 40
F23 80 – – – – 20
Drug release behavior 6292.4. Study of drug release
The dissolution of PPH was performed with the basket method
using a dissolution apparatus (type 1) (Prolabo, France). The
dissolution ﬂuid was 900 mL pH 1.2 buffer solution main-
tained at 37 C and the basket rotational speed was 100 rpm.
To study the effect of the dissolution ﬂuid on release behavior,
drug release tests in both distilled water and phosphate buffer
pH 6.8 were also undertaken. For the dissolution test with pH
change, the drug release in PH 1.2 buffer solution was con-
ducted for a period of one and a half hours. Then the pH
was increased to 6.8 by adding 4.6 g of sodium hydroxide,
3.06 g of monobasic potassium phosphate and 4.005 g of diba-
sic sodium phosphate. An aliquot of 5 mL sample was with-
drawn and replaced with another 5 mL of fresh dissolution
medium at various time intervals. The drug content in the sam-
ples was determined by measuring the absorbance at 323 nm
(n= 3) in a UV–Vis spectrophotometer (Perkin–Elmer,
Germany). During the drug release studies, the matrices were
observed for physical integrity. To study the effect of hydrody-
namic force on drug release, the capsules were tested for disso-
lution at different basket rotational speeds of 25, 50, 100 and
150 rpm.
2.5. Dissolution proﬁle ﬁtting
A least square ﬁtting the experimental dissolution data (cumu-
lative drug release >10% and up to 80%) to the mathematical
equations (power law and zero order) was carried out using a
nonlinear computer program, Scientist for Windows, version
2.1 (MicroMath Scientiﬁc Software, Salt Lake City, UT,
USA). A coefﬁcient of determination (r2) was used to indicate
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where Yobsi and Ycali are observed and calculated values of the
i-th point, respectively; wi is the weight that applies to the i-th
point, n is number of points and p is number of parameters.
3. Results and discussion
The tapped density values of PPH, diluents and other excipi-
ents are presented in Table 1. The tapped density of these
materials depended on the speciﬁc characteristic of individual
materials. The lowest tapped density was found in the case
of chitosan while the tapped density of different grades of
HPMC was in the range of 0.46–0.51 g/mL. There were the
factors affecting drug release of single-unit controlled release
capsules as following.
3.1. Inﬂuence of viscosity grade of matrix former on drug release
The dissolution proﬁles of PPH released from the matrix sys-
tem in HPMC capsules containing different viscosity grades
of HPMC (MethocelK4M, K15M, K100M and low viscosity
grade, E 15LV) powder are shown in Fig. 1. The drug release
from capsules containing HPMC E 15LV was faster than those
containing K4M, K15M and K100M, which showed similar
release proﬁles. The drug release proﬁle from the HPMC
K100M matrix was slightly lower than that containing
HPMC type K4M and K15M. The results demonstrated that

















Figure 1 Dissolution proﬁles of PPH released from the matrix
containing a different viscosity grade HPMC in pH 1.2 buffer
solution (mean ± SD, n= 3).
630 T. Phaechamud, W. Darunkaisornthan 8 h. The dissolutions data of capsules containing HPMC
K4M, K15M and K100M followed the ﬁrst order equation
whereas the dissolution data of capsules containing HPMC
E 15LV ﬁtted well with the zero order equation, as presented
in Table 3.
The utilization of HPMC as a matrix former extended the
drug release owing to the hydrophilic nature of HPMC. It
swelled on contact with water thereafter the medium diffused
into the device. Generally, the thickness of the swollen layer
formed around the matrix core was greater in matrices con-
taining HPMC with higher viscosity grades (Gao et al.,
1996). Increasing the molecular weight of the HPMC powder
from K4M grade to K15M grade had no inﬂuence on the drug
release. A possible explanation was the existence of a limiting
HPMC viscosity, when no further decrease in drug release was
observed, probably due to the time necessary to form the
release-limiting gel barrier (Sung et al., 1996; Krogel and
Bodmeier, 1999). However, the matrix tablets comprising pro-
pranolol hydrochloride (26–64% of HPMC), aminophylline
(16–54% of HPMC) and promethazine hydrochloride (55–Table 3 Comparison of degree of goodness-of-ﬁt from curve ﬁtting
models.
Capsule Power law First order
cd msc cd
HPMC K4M 0.9997 7.59 0.9962
HPMC K15M 0.9983 5.84 0.9947
HPMC K100M 0.9992 6.60 0.9955
HPMC E15LV 0.9989 6.28 0.9845
Lactose 25% 0.9880 3.82 0.9489
Lactose 50% 0.9990 6.33 0.9676
Lactose 75% 0.9979 5.39 0.9306
DCP 25% 0.9939 4.55 0.9381
DCP 50% 0.9972 5.27 0.9726
DCP 75% 0.9999 9.11 0.9187
Xanthan 25% 0.9992 6.53 0.9884
Xanthan 50% 0.9998 8.01 0.9906
Xanthan 75% 0.9995 7.05 0.9972
Chitosan 25% 0.9998 8.19 0.9816
Chitosan 50% 0.9989 6.25 0.9132
Chitosan 75% 0.9990 6.26 0.9257
NaHCO3 20% 0.9995 7.24 0.9871
NaHCO3 40% 0.9982 5.70 0.8680
NaHCO3 60% 0.9979 5.18 0.687686% of HPMC) have not shown signiﬁcantly different release
proﬁles with viscosity grades of HPMC of 850 CP and above
(12,450 and 93,000 cps) (Ford et al., 1985a,b). Higher
HPMC ratios (20% and 30%) in metronidazole matrix tablet
showed no difference on drug release rate when the viscosity
of HPMC was changed (Campos-Aldrete and Villafuerte-
Robles, 1997). Therefore the high amount of HPMC loading
could effectively modulate the drug release which related to
the increased tortuosity and apparently inﬂuenced greater than
the porosity. In addition, the effect of HPMC concentration
on swelling rates was less marked at higher polymer content
(Wan et al., 1995). A saturation state was attained beyond
40% HPMC content of these matrices. The release of repaglin-
ide from microsphere fabricated from HMPC 5 cps and 100
cps was similar but the latter was slightly slower (Sharma
et al., 2015). While the drug release proﬁle from the HPMC
K100M matrix was slightly lower than those of the previous
two viscosity grades, the increased viscosity grade of HPMC
enhanced the thickness of the gel layer and the tortuosity of
the drug diffusion path was increased. In addition, the
HPMC particles of the increased viscosity grades swelled more
slowly and produced swollen particles of smaller volumes. As a
result, matrices made of particles of HPMC with higher viscos-
ity grades showed slower drug release rates than those pre-
pared from HPMC particles with lower viscosity grades
(Tahara et al., 1995).
3.2. Inﬂuence of diluents on drug release
3.2.1. Effect of water soluble and insoluble ﬁllers
Increasing the amount of lactose from 25% to 75% in the
HPMC matrix resulted in an enhancement for the release rate
of PPH (Fig. 2). The increased amount of dibasic calcium
phosphate in the HPMC matrices led to the increasing of drug
release rate (Fig. 3). By comparison, the matrix containing
100% dibasic calcium phosphate showed a greater drug releaseof drug dissolution in pH 1.2 buffer solution to different release
Higuchi’s Zero order
msc cd msc cd msc
5.20 0.9480 2.59 0.9851 3.85
4.89 0.9664 3.03 0.9734 3.26
5.04 0.9894 4.18 0.9805 3.58
3.81 0.9610 2.88 0.9858 3.89
2.57 0.9641 2.93 0.9844 3.76
3.03 0.9710 3.14 0.9885 3.38
2.17 0.9810 3.47 0.9785 3.34
2.42 0.9307 2.31 0.9904 4.29
3.20 0.9751 3.30 0.9761 3.33
2.01 0.9573 2.65 0.9916 4.28
4.06 0.9916 4.38 0.9799 3.51
4.27 0.9814 3.59 0.9899 4.20
5.50 0.9827 3.69 0.9737 3.27
3.66 0.9782 3.49 0.9816 3.66
2.08 0.9013 1.95 0.9968 5.39
2.15 0.9596 2.01 0.9990 6.46
3.98 0.9773 3.42 0.9847 3.81
1.58 0.9365 2.31 0.9966 5.26

















Figure 2 Dissolution proﬁles of PPH released from capsules
ﬁlled with HPMC matrices containing different amounts of lactose


















Figure 3 Dissolution proﬁles of PPH released from capsules
ﬁlled with HPMC matrices containing different amounts of
dibasic calcium phosphate (D) in pH 1.2 buffer solution


















Figure 4 Dissolution proﬁles of PPH released from capsules
ﬁlled with various polymers matrix (HPMC K15M (H), xanthan
gum (X) and chitosan (C)) in pH 1.2 buffer solution (mean ± SD,
n= 3).
Drug release behavior 631than the matrix containing only lactose as a diluent. The disso-
lution data from matrices containing only lactose and dibasic
calcium phosphate were not used for the curve ﬁtting because
of the apparent fast release of the drug from the capsule.
However, the incorporation of lactose or dibasic calcium phos-
phate in the HPMC matrix contributed to a drug release rate
close to zero-order as presented in Table 3. The magnitude
of the exponent n from the curve ﬁtting to a power law equa-
tion could indicate a release mechanism such as Fickian diffu-
sion, case II transport, or anomalous transport. In the present
study (cylindrical shape) the limits considered were n= 0.45
(indicates a classical Fickian diffusion-controlled drug release)
and n= 0.89 (indicates a case II relaxational release transport:
polymer relaxation controls drug delivery). Values of n
between 0.45 and 0.89 can be regarded as indicators of both
phenomena (transport corresponding to coupled drug diffu-
sion in the hydrated matrix and polymer relaxation), com-
monly called anomalous non-Fickian transport (Lotﬁpour
et al., 2004). The k value can be regarded as a power law
release constant with bigger values leading to faster drug
release. Mathematically, an increasing n values bigger than
1.0 allows for a more desirable incremental release. To achieve
a delayed release pattern that was therapeutically useful, n val-
ues were expected to be bigger and k values to be smaller with
a prerequisite of acceptable lag time (Walker and Wells, 1982).
From the release exponent (n), the release mechanism of for-
mulations containing 25%, 50% and 75% lactose or dibasic
calcium phosphate indicated non-Fickian transport(Table 3). The incorporation of lactose or dibasic calcium
phosphate in the HPMC matrix system decreased the concen-
tration of polymer in gel layers. Therefore, the diffusion of a
medium into the capsule was facilitated and then the diffusion
of the drug from the matrix was enhanced. As a result, the
release rate of the drug from the matrices was increased.
Increasing the polymer/ﬁller ratio increased the release rate
since the diffusivity of the drug in the gel layer was enhanced
(Takka, 2003; Takka et al., 2001). Lactose or dibasic calcium
phosphate exhibited the similar impact on the release of PPH
from HPMC matrices because both of them could dissolve in
this buffer.
3.2.2. Effect of polymer
The dissolution proﬁles of the drug from capsules ﬁlled with
HPMC K15M, xanthan gum and chitosan, are shown in
Fig. 4. All polymers sustained the drug release in pH 1.2 buffer
solution for longer than 8 h, whereas the capsule ﬁlled with
only chitosan prolonged the drug release for 4 h following
the immediate drug release. The amino groups onto chitosan
structure could be protonated in acidic media and then dis-
solved however this alteration gradually occurred (Tungtong
et al., 2012). Thus the burst release at 4 h was owing to the
complete protonation and the solubilized chitosan could not
retard the drug release anymore. The drug release from
HPMC K15M matrix was slower than those containing other
polymers however it was slightly different from that containing
xanthan.
The release proﬁle of the formulation containing 50% xan-
than gum in the HPMC matrix displayed slightly slower
release than that containing only HPMC. However the release
proﬁle of the formulation containing 25% xanthan gum in the
HPMC matrix showed a similar drug release proﬁle to the sys-
tem containing only HPMC (Fig. 5). The PPH released from
HPMC–xanthan gum matrices was rather complex, because
both HPMC and xanthan gum are hydrophilic polymers
which, upon contact with aqueous ﬂuid, are able to form quite
a viscous gel. Xanthan gum could increase the viscous gel layer
around the matrix core. Furthermore, synergism attributed to
the intermolecular hydrogen-bonding between them could
occur. The addition of sodium carboxymethylcellulose
(NaCMC) to HPMC matrix increased the viscosity of the sys-
tem since there was a strong hydrogen bonding between the
















Figure 5 Dissolution proﬁles of PPH released from capsules
ﬁlled with HPMC matrices containing different amounts of
xanthan gum (X) in pH 1.2 buffer solution (mean ± SD, n= 3).
Table 4 Estimate parameters from curve ﬁtting of drug
dissolution in pH 1.2 buffer solution to power law expression.
Capsule k± sd^101 tl ± sd (hr) n± sd
HPMC K4M 0.1835 ± 0.0039 0.59 ± 0.04 0.66 ± 0.01
HPMC K15M 0.2081 ± 0.0081 0.73 ± 0.06 0.60 ± 0.02
632 T. Phaechamud, W. DarunkaisornHPMC, leading to strong cross-linking between the two poly-
mers (Takka et al., 2001). Thus there was a possibility of inter-
action between xanthan gum and HPMC based on hydrogen
bonding similar to the interaction between HPMC and Na
CMC (Takka et al., 2001) or collagen (Ding et al., 2015) as
previously reported.
Hence, the formulation containing 50% xanthan gum and
50% HPMC increased the viscosity of the gel layer and subse-
quently retarded the drug diffusion from the capsule. The
other reason for the retardation of drug release with xanthan
gum could be the ionic interactions between the drug and this
anionic polymer. There was a considerable interaction between
PPH and anionic polymers depending on the carboxyl func-
tional groups of the anionic polymers (Varma et al., 2005; de
la Torre et al., 2003).
In pH 1.2 buffer solution, the drug release from the matrix
system containing chitosan was faster, as shown in Fig. 6. The
formulation containing only chitosan exhibited immediate
release after 4 h. The use of pure chitosan formulation in oral
administration was limited owing to its fast dissolution in the
acidic environment of the stomach. Some researchers noted
that at least chitosan of 80% was needed to achieve the proper
sustained release tablets (Sawayanagi et al., 1982). Capsules
containing 75% chitosan in HPMCmatrices also exhibited fast
release after 4 h. This formulation released PPH nearly to
100% at 6 h. All formula comprising chitosan in HPMCmatri-
ces exhibited faster drug release compared to the matrix con-



















Figure 6 Dissolution proﬁles of PPH released from capsules
ﬁlled with HPMC matrices containing different amounts of
chitosan (C) in pH 1.2 buffer solution (mean ± SD, n= 3).The dissolution data of capsule containing HPMC–xanthan
gum matrices were best ﬁtted with the ﬁrst order model
(Table 3). Their release mechanism was non-Fickian transport
with n values ranging from 0.57 to 0.65 (Table 4). The dissolu-
tion data of the formulation containing HPMC-chitosan
matrices ﬁtted well with the zero order as presented in
Table 3. The release mechanism of the formulation containing
50% and 75% chitosan in HPMC matrices was non-Fickian
transport (Table 4). The hydrophilicity of chitosan, due to
the presence of amine and hydroxy functional groups in its
repeat unit, makes the polymer soluble in diluted acidic solu-
tions. It is insoluble in water but soluble at pH values under
6.5 in most acidic media (Oungbho and Mu¨ller, 1997).
Therefore, the dissolution proﬁle of PPH released from the chi-
tosan matrix exhibited fast release after 4 h in pH 1.2 buffer
solution. The incorporation of chitosan in HPMC matrices
decreased the amount of drug released. Because of the gel
forming ability of chitosan, synergism attributed to the inter-
molecular hydrogen-bonding between hydroxyl functional
groups on chitosan, and hydroxyl groups on HPMC.
However the release of PPH was increased as the chitosan con-
tent was increased owing to its solubility in an acidic
environment.
3.2.3. Effect of sodium bicarbonate
The incorporation of 40% sodium bicarbonate (S) into the
HPMC matrix prolonged drug release in pH 1.2 buffer solu-
tion (Fig. 7). Increasing proportion of sodium bicarbonate
up to 60% in HPMC-bicarbonate matrices provided the slow
drug release during the ﬁrst 2 h and thereafter faster release.
The capsule containing 20% sodium bicarbonate in the
HPMC matrix showed similar drug release to the formulation
containing only HPMC during the ﬁrst 4 h. Subsequently, this
formulation exhibited faster drug release than that containing
only HPMC. The dissolution data of the formulations contain-
ing 40% and 60% sodium bicarbonate were ﬁtted well with the
zero order, while the formulation containing 20% sodiumHPMC K100M 0.1855 ± 0.0062 0.51 ± 0.06 0.60 ± 0.02
HPMC E15LV 0.2179 ± 0.0095 0.53 ± 0.07 0.66 ± 0.02
Lactose 25% 1.8687 ± 0.0493 0.49 ± 0.49 0.73 ± 0.11
Lactose 50% 2.8426 ± 0.0081 0.57 ± 0.03 0.64 ± 0.02
Lactose 75% 3.4537 ± 0.0178 0.72 ± 0.06 0.62 ± 0.03
DCP 25% 1.7769 ± 0.0267 0.40 ± 0.23 0.79 ± 0.07
DCP 50% 2.8539 ± 0.0151 0.52 ± 0.06 0.64 ± 0.03
DCP 75% 2.9159 ± 0.0032 0.64 ± 0.01 0.72 ± 0.01
Xanthan 25% 2.3112 ± 0.0048 0.69 ± 0.03 0.57 ± 0.11
Xanthan 50% 1.8118 ± 0.0042 0.78 ± 0.04 0.65 ± 0.11
Xanthan 75% 2.1705 ± 0.0074 1.03 ± 0.06 0.58 ± 0.02
Chitosan 25% 1.5776 ± 0.0152 0.07 ± 0.10 1.01 ± 0.05
Chitosan 50% 1.7580 ± 0.0132 0.28 ± 0.11 0.84 ± 0.03
Chitosan 75% 2.3897 ± 0.0031 0.48 ± 0.01 0.64 ± 0.01
NaHCO3 20% 2.0049 ± 0.0049 0.63 ± 0.03 0.66 ± 0.01
NaHCO3 40% 1.3499 ± 0.0149 1.34 ± 0.15 0.86 ± 0.05


















Figure 7 Dissolution proﬁles of PPH released from capsules
ﬁlled with HPMC matrices containing different amounts of

















Phosphate buffer pH 6.8
HCl buffer pH 1.2
pH change
Figure 8 Dissolution proﬁles of PPH released from capsules
ﬁlled with HPMC matrices containing 75% lactose in different pH



















Figure 9 Dissolution proﬁles of PPH released from capsules
ﬁlled with HPMC matrices containing 75% lactose by varying
rotation speed of the paddle in pH 1.2 buffer solution
(mean ± SD, n= 3).
Drug release behavior 633bicarbonate in the HPMC matrix was close to the ﬁrst order
model, as presented in Table 3. The release mechanism of all
formula containing sodium bicarbonate in HPMC matrices
was non-Fickian transport (Table 4). Since sodium bicarbon-
ate posed as the effervescence in high concentration acid con-
ditions, it promoted a sustained drug release when a suitable
concentration was employed. Sodium bicarbonate provided
gas generation in pH 1.2 buffer solution. Therefore, the air
bubbles which appeared in the swollen matrix posed as a trans-
port barrier as previously reported (Ching et al., 2008). It has
been reported that the incorporation of sodium bicarbonate
into HPMC K4Mmatrix tablets reduced the release rate of dil-
tiazem hydrochloride, since the in situ chemical interaction
within the gelled structure might induce the alteration of
matrix-swelling dynamics and the inhibition of drug dissolu-
tion (Pillay and Fassihi, 1999). In addition, the modiﬁcation
in micro environmental pH by adding sodium bicarbonate into
this matrix leading to partly neutralization of PPH to free
base, leading to greater drug release retardation in acidic
media. The pH enhancement for micro-environment of sodium
alginate matrix minimized the crack formation and prolonged
the drug release by retarding the conversion of this polymer to
alginic acid (Ching et al., 2008). Therefore the neutralization
action of pH-modiﬁer such as sodium bicarbonate was syner-
gistically enhanced in the presence of carbon dioxide barrier
formed by effervescing sodium bicarbonate, reducing drug
release in the acid medium. However the high loading amount
of sodium bicarbonate generated enough carbon dioxide after
exposure to the acidic medium to expel and promote the gel
erosion thereafter the fast drug release was evident for the
60% sodium bicarbonate incorporated in this matrix because
the neutralization effect on drug release might have been coun-
tered by strong gel erosion. The matrix could form the mild
gelation and mild gel erosion for the addition of 20% sodium
bicarbonate thus the drug release was unaffected.
3.3. Inﬂuence of pH of dissolution medium and hydrodynamic
force on drug release
To simulate the environment of the gastrointestinal tract, the
effect of pH of the dissolution medium on the release of
PPH from capsules was investigated A system containing
75% lactose and 25% HPMC was chosen for further investiga-
tion of the inﬂuence of the pH of the dissolution medium onthe PPH release (Fig. 8). The drug release was faster in distilled
water than that in pH 1.2 buffer solution, phosphate buffer pH
6.8 and pH change, while the release in the three latter disso-
lution ﬂuids was similar. HPMC is non-ionic therefore acidic
condition slightly affected the solubility and swelling (de la
Torre et al., 2003). The hydrogel based on high-viscosity
HPMC was known to deliver the drug at a constant rate,
which was independent of the hydration, gel viscosity and rel-
ative permeability of the dosage form, because the drug release
rate was related directly to the drug solubility (Varma et al.,
2005). PPH is a weakly basic drug, therefore, it should exhibit
pH-dependent release from the matrix due to its pH-dependent
solubility. Its solubility was found to be 225 mg/mL at pH 1.2,
130 mg/mL at pH 6.8 and 360 mg/mL in water. The release of
PPH was faster in water and 0.1 N HCl compared to that in a
phosphate buffer (de la Torre et al., 2003). However, the study
indicated that PPH did not demonstrate the pH-dependent sol-
ubility from the HPMC matrix granule ﬁlled into the capsule.
The enhanced rotational speed or hydrodynamic force
increased the drug release (Fig. 9). There was a more rapid ero-
sion of the matrix at higher stirring rates because of the
increased rate of detachment of polymer chains away from
the matrix surface. This led to a thinner layer of gel forming
at the surface of the dosage form at higher agitation rate
(Goole et al., 2007) therefore the drug release from this matrix
capsule changed easily due to physical agitation and probably
peristaltic movement in the gastrointestinal tract.
634 T. Phaechamud, W. Darunkaisorn4. Conclusion
The utilization of HPMC as a matrix former extended the
release time of PPH from capsules. The viscosity grade of
HPMC affected the drug release. The increased amount of ﬁl-
lers (lactose and dibasic calcium phosphate) increased the
release rate of PPH from the HPMC matrices. Types and
amounts of polymer apparently affected the PPH release from
HPMC matrices. The physiochemical properties of polymers
and the interaction between HPMC and polymers were the
important factors for the prolongation of the drug release.
The release mechanism from the HPMC-based matrices in
capsules was non-Fickian transport.
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